

## Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended June 30, 2021

Revenue (\$ thousands)	2019				2020				2021	2021	2019	2020
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	FY	FY
<b>NeuroStar Capital (1)</b>	<b>\$2,939</b>	<b>\$4,034</b>	<b>\$4,264</b>	<b>\$4,959</b>	<b>\$2,410</b>	<b>\$2,224</b>	<b>\$2,438</b>	<b>\$3,446</b>	<b>\$1,589</b>	<b>\$2,441</b>	<b>\$16,196</b>	<b>\$10,518</b>
<i>YoY Change</i>	54%	23%	24%	14%	-18%	-45%	-43%	-31%	-34%	10%	25%	-35%
<b>NeuroStar Operating Lease (2)</b>	<b>\$182</b>	<b>\$187</b>	<b>\$184</b>	<b>\$177</b>	<b>\$155</b>	<b>\$114</b>	<b>\$88</b>	<b>\$79</b>	<b>\$108</b>	<b>\$55</b>	<b>\$730</b>	<b>\$437</b>
<i>YoY Change</i>	-29%	3%	-31%	-24%	-15%	-39%	-52%	-55%	-31%	-51%	-22%	-40%
<b>Other (3)</b>	<b>\$229</b>	<b>\$407</b>	<b>\$167</b>	<b>\$278</b>	<b>\$29</b>	<b>\$0</b>	<b>\$15</b>	<b>\$96</b>	<b>\$58</b>	<b>\$81</b>	<b>\$1,081</b>	<b>\$140</b>
<i>YoY Change</i>	11%	239%	-21%	50%	-87%	-100%	-91%	-66%	100%	100%	50%	-87%
<b>Total U.S. NeuroStar Advanced Therapy System Revenues</b>	<b>\$3,350</b>	<b>\$4,628</b>	<b>\$4,616</b>	<b>\$5,413</b>	<b>\$2,594</b>	<b>\$2,338</b>	<b>\$2,541</b>	<b>\$3,620</b>	<b>\$1,755</b>	<b>\$2,577</b>	<b>\$18,007</b>	<b>\$11,094</b>
<i>YoY Change</i>	41%	30%	18%	14%	-23%	-49%	-45%	-33%	-32%	10%	23%	-38%
<b>Total U.S. Treatment Sessions Revenues</b>	<b>\$8,778</b>	<b>\$10,847</b>	<b>\$10,252</b>	<b>\$11,243</b>	<b>\$8,193</b>	<b>\$6,547</b>	<b>\$9,083</b>	<b>\$11,029</b>	<b>\$9,629</b>	<b>\$10,801</b>	<b>\$41,120</b>	<b>\$34,852</b>
<i>YoY Change</i>	21%	22%	11%	13%	-7%	-40%	-11%	-2%	18%	65%	17%	-15%
<b>Total U.S. Other Revenues</b>	<b>\$418</b>	<b>\$415</b>	<b>\$426</b>	<b>\$374</b>	<b>\$390</b>	<b>\$382</b>	<b>\$404</b>	<b>\$397</b>	<b>\$419</b>	<b>\$431</b>	<b>\$1,633</b>	<b>\$1,574</b>
<i>YoY Change</i>	16%	1%	9%	-12%	-7%	-8%	-5%	6%	7%	13%	3%	-4%
<b>Total U.S. Revenues</b>	<b>\$12,546</b>	<b>\$15,890</b>	<b>\$15,294</b>	<b>\$17,030</b>	<b>\$11,177</b>	<b>\$9,267</b>	<b>\$12,029</b>	<b>\$15,046</b>	<b>\$11,802</b>	<b>\$13,809</b>	<b>\$60,760</b>	<b>\$47,519</b>
<i>YoY Change</i>	26%	23%	13%	13%	-11%	-42%	-21%	-12%	6%	49%	18%	-22%
<b>Total International Revenues</b>	<b>\$182</b>	<b>\$682</b>	<b>\$706</b>	<b>\$326</b>	<b>\$299</b>	<b>\$474</b>	<b>\$419</b>	<b>\$533</b>	<b>\$486</b>	<b>\$394</b>	<b>\$1,896</b>	<b>\$1,725</b>
<i>YoY Change</i>	1%	93%	222%	-40%	64%	-31%	-41%	64%	63%	-17%	46%	-9%
<b>Total Revenues</b>	<b>\$12,728</b>	<b>\$16,572</b>	<b>\$16,000</b>	<b>\$17,356</b>	<b>\$11,476</b>	<b>\$9,741</b>	<b>\$12,448</b>	<b>\$15,579</b>	<b>\$12,288</b>	<b>\$14,203</b>	<b>\$62,656</b>	<b>\$49,244</b>
<i>YoY Change</i>	25%	25%	16%	11%	-10%	-41%	-22%	-10%	7%	46%	19%	-21%
<b>U.S. Operating and Financial Metrics</b>	2019				2020				2021		2019	2020
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	FY	FY
<b>Total NeuroStar Systems Sold (4)</b>	<b>43</b>	<b>61</b>	<b>68</b>	<b>78</b>	<b>38</b>	<b>35</b>	<b>39</b>	<b>54</b>	<b>23</b>	<b>36</b>	<b>250</b>	<b>166</b>
<i>YoY Change</i>	79%	42%	45%	28%	-12%	-43%	-43%	-31%	-39%	3%	43%	-34%
<b>Average Revenue Per Active Site (\$) (5)</b>	<b>\$12,415</b>	<b>\$14,718</b>	<b>\$13,177</b>	<b>\$13,497</b>	<b>\$9,418</b>	<b>\$7,406</b>	<b>\$10,218</b>	<b>\$12,133</b>	<b>\$10,512</b>	<b>\$12,001</b>	<b>\$58,162</b>	<b>\$40,060</b>
<i>YoY Change</i>	NA	29%	17%	17%	-24%	-50%	-22%	-10%	12%	62%	12%	-31%

(1) = Revenue from Capital Sales and Sales Type Leases

(2) = Revenue derived from Operating Lease revenue during the period

(3) = Primarily includes revenue derived from Treatment Coils in US

(4) = Includes all systems sold during the period, both as Capital Sales or Sales-Type-Leases

(5) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)